1026442-85-2

Basic information

• Product Name: 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1026442-85-2
• Molecular Weight: 798.977
• Mol File: 1026442-85-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester(1026442-85-2)
• EPA Substance Registry System: 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester(1026442-85-2)

Safety Data

• Hazardous Substances Data: 1026442-85-2(Hazardous Substances Data)

Upstream product

• 138109-37-2 Asp(OBzl)-Phe-OBzl 
• 138108-43-7 Boc-Asp(OBzl)-Phe-OBzl 
• 142247-38-9 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]butanoic acid 
• 118517-08-1 (S)-3-tert-Butoxycarbonylamino-4-isopropoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 102878-73-9 γ-(pyridin-4-yl)butyric acid 
• 90950-44-0 4-(piperidin-4-yl)butanoic acid 
• 962-39-0 L-Phenylalanine benzyl ester 
• 92501-98-9 ethyl 2-ethoxycarbonyl-4-(pyrid-4-yl)-butanoate 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 100-43-6 4-vinylpyridine 

Relevant articles and documents

Design of a new class of orally active fibrinogen receptor antagonists

The integrin receptor recognition sequence Arg-Gly-Asp was successfully used as a template from which to develop a series of potent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of action. Simple modifications centered on the Arg and Gly residues quickly led to a modified peptide (1) with significantly enhanced ability to inhibit in vitro platelet aggregation. Substitution of the guanidino group in 1 by piperidine provided 3, which showed not only a further increase in potency but also a modest degree of oral efficacy. Finally, exploration of the nature of the C-terminal amino acid, with respect to its side-chain functionality and the carboxy terminus, yielded a group of molecules that showed excellent in vitro potency for inhibiting platelet aggregation, excellent integrin selectivity, a high level of oral efficacy, and an extended duration of action.